Korber A, et al. - This trial effectuated an inspection of the prior and concomitant use of psoriasis therapies in enrollees receiving secukinumab. It also examined the duration of transition periods from prior treatments to secukinumab. Maximum individuals reported a high disease burden. It was revealed that the use of concomitant treatment increased with the disease severity. Prior treatment served as the basis for the duration of the transition period.

Methods

• PROSPECT was an ongoing 24-week, single-cohort, non-interventional study.
• The eligible participants consisted of patients with moderate to severe psoriasis with a decision to receive secukinumab.

Results

• Maximum enrollees were male (491/796, 61.7%), with a mean age of 47.7 years (SD 13.7).
• The baseline Psoriasis Area and Severity Index (PASI) was available for 92.4% (744/805) of candidates and mean baseline PASI was 17.5 (SD 13.1, n=744).
• 93.4% (752/805) of subjects displayed signs of high disease severity.
• An increase was noted in the use of concomitant treatment with the number of signs.
• 10%, 40%, and 28% of subjects received topical, conventional systemic, or biologic treatments as their last prior psoriasis therapy, respectively and 22% of subjects had not received any psoriasis therapy, within the last 12 months prior to inclusion.
• High discontinuation of prior treatment was reported owing to the adverse events in individuals with conventional systemic treatment (93/413, 22.5%) than biologic treatment (5/210, 2.4%).
• The median duration of the transition period was 14.0, 30.5, and 38.0 days for prior topical, conventional systemic, and biologic treatments, respectively.